1-5 of 5
Orville Kolterman
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Response to Comment on Braffett et al. Association of Insulin Dose, Cardiometabolic Risk Factors, and Cardiovascular Disease in Type 1 Diabetes During 30 Years of Follow-up in the DCCT/EDIC Study. Diabetes Care 2019;42:657–664

Barbara H. Braffett, Samuel Dagogo-Jack, Ionut Bebu, William I. Sivitz, Mary Larkin, Orville Kolterman, John M. Lachin
Journal: Diabetes Care
Diabetes Care 2019;42(8):e137
https://doi.org/10.2337/dci19-0026
Published: 12 July 2019
View article titled, Response to Comment on Braffett et al. Association of Insulin Dose, Cardiometabolic Risk Factors, and Cardiovascular Disease in Type 1 Diabetes During 30 Years of Follow-up in the DCCT/EDIC Study. Diabetes Care 2019;42:657–664
Open the PDF for Response to Comment on Braffett et al. Association of Insulin Dose, Cardiometabolic Risk Factors, and Cardiovascular Disease in Type 1 Diabetes During 30 Years of Follow-up in the DCCT/EDIC Study. Diabetes Care 2019;42:657–664 in another window
Journal Articles

Association of Insulin Dose, Cardiometabolic Risk Factors, and Cardiovascular Disease in Type 1 Diabetes During 30 Years of Follow-up in the DCCT/EDIC Study

Barbara H. Braffett, Samuel Dagogo-Jack, Ionut Bebu, William I. Sivitz, Mary Larkin, Orville Kolterman, John M. Lachin
Journal: Diabetes Care
Diabetes Care 2019;42(4):657–664
https://doi.org/10.2337/dc18-1574
Published: 06 February 2019
View article titled, Association of Insulin Dose, Cardiometabolic Risk Factors, and Cardiovascular Disease in Type 1 Diabetes During 30 Years of Follow-up in the DCCT/EDIC Study
Open the PDF for Association of Insulin Dose, Cardiometabolic Risk Factors, and Cardiovascular Disease in Type 1 Diabetes During 30 Years of Follow-up in the DCCT/EDIC Study in another window
Includes: Supplementary data
Journal Articles

Pramlintide Improved Glycemic Control and Reduced Weight in Patients With Type 2 Diabetes Using Basal Insulin

Matthew Riddle, MD, Juan Frias, MD, Bei Zhang, MD, Holly Maier, PHD, Carl Brown, PHD, Karen Lutz, PHD, Orville Kolterman, MD
Journal: Diabetes Care
Diabetes Care 2007;30(11):2794–2799
https://doi.org/10.2337/dc07-0589
Published: 01 November 2007
View article titled, Pramlintide Improved Glycemic Control and Reduced Weight in Patients With Type 2 Diabetes Using Basal Insulin
Open the PDF for Pramlintide Improved Glycemic Control and Reduced Weight in Patients With Type 2 Diabetes Using Basal Insulin in another window
Journal Articles

Effect of Adjunctive Pramlintide Treatment on Treatment Satisfaction in Patients With Type 1 Diabetes

David G. Marrero, PHD, John Crean, PHD, Bei Zhang, MD, Terrie Kellmeyer, PHD, Maurice Gloster, MD, Kathrin Herrmann, PHD, Richard Rubin, PHD, Naomi Fineberg, PHD, Orville Kolterman, MD
Journal: Diabetes Care
Diabetes Care 2007;30(2):210–216
https://doi.org/10.2337/dc06-1026
Published: 01 February 2007
View article titled, Effect of Adjunctive Pramlintide Treatment on Treatment Satisfaction in Patients With Type 1 Diabetes
Open the PDF for Effect of Adjunctive Pramlintide Treatment on Treatment Satisfaction in Patients With Type 1 Diabetes in another window
Journal Articles

A Double-Blind, Placebo-Controlled Trial Assessing Pramlintide Treatment in the Setting of Intensive Insulin Therapy in Type 1 Diabetes

Steve Edelman, MD, Satish Garg, MD, Juan Frias, MD, David Maggs, MD, Yan Wang, PHD, Bei Zhang, MD, MS, Susan Strobel, PHD, Karen Lutz, PHD, Orville Kolterman, MD
Journal: Diabetes Care
Diabetes Care 2006;29(10):2189–2195
https://doi.org/10.2337/dc06-0042
Published: 01 October 2006
View article titled, A Double-Blind, Placebo-Controlled Trial Assessing Pramlintide Treatment in the Setting of Intensive Insulin Therapy in Type 1 Diabetes
Open the PDF for A Double-Blind, Placebo-Controlled Trial Assessing Pramlintide Treatment in the Setting of Intensive Insulin Therapy in Type 1 Diabetes in another window